Biotechnology major Biocon today said it has received EU GMP certification for its sterile drug product manufacturing facility in Bengaluru.
"This facility is used for the manufacture of Biocon's portfolio of biosimilars," a company spokesperson said.
Earlier in May, in a regulatory filing Biocon had said it had received a preliminary report from the European Regulator post inspection of its sterile drug product facility in Bengaluru in March 2018.
"The report lists six major observations with no observation classified as critical. We will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period," a company spokesperson had said.
Shares of Biocon Ltd today closed at Rs 628.15 on BSE, down 0.02 per cent from previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)